Brought to you by 
Genzyme to help develop Osiris' Prochymal
Aug 2007
Executive Summary
Genzyme and Osiris (stem cell therapies) have signed an alliance focused on the creation of drugs for radiological emergencies, including nuclear terrorism strikes.
Deal Industry
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R+D and Marketing-Licensing
- Intra-Biotech Deal
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
Advertisement
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Genzyme to help develop Osiris' Prochymal
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice